Coya Therapeutics (COYA) Depreciation & Amortization (CF) (2022 - 2026)
Coya Therapeutics (COYA) reported Depreciation & Amortization (CF) of $2807.0 for Q1 2026, down 58.96% on a YoY basis from $6840.0 in Q1 2025, and down 58.97% sequentially from $6841.0 in Q4 2025.
Coya Therapeutics (COYA) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Coya Therapeutics (COYA) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $2807.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 58.96% year-over-year to $2807.0; the trailing twelve-month figure through Mar 2026 stood at $23328.0 (down 14.74% YoY), and the FY2025 full-year result was $27361.0, changed 0.0% from the prior year.
- Depreciation & Amortization (CF) fell to $2807.0 in Q1 2026, from $6841.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $12455.0 in Q3 2022 to a low of $2807.0 in Q1 2026.
- A 5-year average of $6603.0 and a median of $6840.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 69.6% in 2023 and tumbled 58.96% in 2026, its largest moves.
- Tracing COYA's Depreciation & Amortization (CF) over 5 years: stood at $6840.0 in 2022, then changed by 0.0% to $6840.0 in 2023, then changed by 0.0% to $6840.0 in 2024, then grew by 0.01% to $6841.0 in 2025, then plunged by 58.97% to $2807.0 in 2026.
- Business Quant data shows COYA's Depreciation & Amortization (CF) at $2807.0 in Q1 2026, $6841.0 in Q4 2025, and $6840.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Coya Therapeutics | 97.14 Mn | 46.42 Mn | - | 2,807.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,807.00 |
| Mar 31, 2026 | 2,807.00 |
| Dec 31, 2025 | 6,841.00 |
| Dec 31, 2025 | 6,841.00 |
| Sep 30, 2025 | 6,840.00 |
| Sep 30, 2025 | 6,840.00 |
| Jun 30, 2025 | 6,840.00 |
| Jun 30, 2025 | 6,840.00 |
| Mar 31, 2025 | 6,840.00 |
| Mar 31, 2025 | 6,840.00 |
| Dec 31, 2024 | 6,840.00 |
| Dec 31, 2024 | 6,840.00 |
| Sep 30, 2024 | 6,841.00 |
| Sep 30, 2024 | 6,841.00 |
| Jun 30, 2024 | 6,840.00 |
| Jun 30, 2024 | 6,840.00 |
| Mar 31, 2024 | 6,840.00 |
| Mar 31, 2024 | 6,840.00 |
| Dec 31, 2023 | 6,840.00 |
| Dec 31, 2023 | 6,840.00 |